Here’s what you should know:
1. Vosevi is a fixed-dose, combination tablet which consists of sofosbuvir, velpatasvir and voxilaprevir. All three drugs are FDA approved.
2. According to a release, this is the first treatment for patients who previously used a direct-acting antiviral for HCV.
3. Vosevi is an option for patients who did not have success with a direct-acting agent.
4. Gilead’s President and CEO John Milligan said in a release, “The evolution of Gilead’s portfolio of HCV single-tablet regimens has been driven by our commitment to address previously unmet needs and put the possibility of cure within reach for as many HCV patient populations as possible.”
http://www.gilead.com/news/press-releases/2017/7/us-food-and-drug-administration-approves-gileads-vosevi-sofosbuvirvelpatasvirvoxilaprevir-for-retreatment-of-adults-with-chronic-hepatitis-c-virus
More articles on gastroenterology:
GI center to know: Spokane Digestive Disease Center
Solutions for every setting — Gastroenterologist Dr. Michael DiMarino on the gMed™ suite
GI leader to know: Dr. Paul Craig of Valley Gastroenterology
